Cancer Genetics (Cancer Genetics) Debt-to-Equity : 0.09 (As of Dec. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Cancer Genetics Debt-to-Equity?

Cancer Genetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $0.26 Mil. Cancer Genetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $0.10 Mil. Cancer Genetics's Total Stockholders Equity for the quarter that ended in Dec. 2020 was $3.98 Mil. Cancer Genetics's debt to equity for the quarter that ended in Dec. 2020 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cancer Genetics's Debt-to-Equity or its related term are showing as below:

CGIX's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Cancer Genetics Debt-to-Equity Historical Data

The historical data trend for Cancer Genetics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Genetics Debt-to-Equity Chart

Cancer Genetics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-Equity

Get a 7-Day Free Trial

0.20

0.41

0.38

0.22

0.09

Cancer Genetics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Debt-to-Equity	Get a 7-Day Free Trial															0.22	0.26	0.22	0.04	0.09

Competitive Comparison of Cancer Genetics's Debt-to-Equity

For the Biotechnology subindustry, Cancer Genetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Genetics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cancer Genetics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cancer Genetics's Debt-to-Equity falls into.

Cancer Genetics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cancer Genetics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.258	+	0.104)	/	3.98
	=	0.09

Cancer Genetics's Debt to Equity Ratio for the quarter that ended in Dec. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.258	+	0.104)	/	3.98
	=	0.09

Cancer Genetics (NAS:CGIX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cancer Genetics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cancer Genetics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Genetics (Cancer Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cancer Genetics Inc (NAS:CGIX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Route 17 North, 2nd Floor, Meadows Office Complex, Rutherford, NJ, USA, 07070

Website

http://www.cancergenetics.com

Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.

Executives

Ralf Brandt	officer: President, Discovery Services	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Glenn Miles	officer: Chief Financial Officer	C/O CANCER GENETICS INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Franklyn G Prendergast	director
Chaganti Raju S.k.	director	201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Edmund Cannon	director	201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Geoffrey E. Harris	director	8 HARTLEY FARMS ROAD, MORRISTOWN NJ 07960
Howard Mcleod	director	201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
John Pappajohn	director	1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
John A Roberts	officer: Chief Executive Officer	C/O CANCER GENETICS, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William Lansing Finger	officer: EVP Precision Medicine	201 ROUTE 17N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Brian Mccartney	officer: Chief Commercial Officer	C/O CANCER GENETICS, INC., 201 ROUTE 17 N, 2ND FLOOR, RUTHERFORD NJ 07070
Rita Shaknovich	officer: Chief Medical Officer	C/O CANCER GENETICS, INC. 201 ROUTE 17N, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas F Widmann	director	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael J. Welsh	director	UNIV. OF IOWA CARVER COLLEGE OF MEDICINE, DEPT. OF INTERNAL MEDICINE, 500 EMRB, IOWA CITY IA 52242
Igor Gitelman	officer: Chief Accounting Officer	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070